文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-617 在同时性高瘤负荷转移性激素敏感性前列腺癌中显示出有前景的治疗活性:一项初步经验

Promising Therapeutic Activity of 177 Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer : A Pilot Experience.
PubMed 文献 · Clin Nucl Med · 2023-12-04

本研究纳入10例同时性高瘤负荷转移性激素敏感性前列腺癌患者,接受177Lu-PSMA-617治疗(中位累积活度32.4 GBq,1-6个周期)。5例(50%)PSA不可测,9例(90%)PSA较基线下降≥50%,9例可评估影像者中7例(77.8%)客观缓解,中位影像学无进展生存期24个月,未发生3/4级不良事件。作者认为该药似乎是有效且安全的有前景治疗选择。

要点

  • 10例同时性高瘤负荷mHSPC患者接受177Lu-PSMA-617,5例(50%)达到PSA不可测(≤0.2 ng/mL)。
  • 9例(90%)PSA较基线下降≥50%,可评估影像的9例中7例(77.8%)客观缓解。
  • 中位影像学无进展生存期24个月(95%CI 18-30),中位总生存期未达到,无3/4级不良事件。

核心结论

  • 作者认为177Lu-PSMA-617似乎是同时性高瘤负荷转移性激素敏感性前列腺癌患者有效且安全的有前景治疗选择。

研究设计与样本

  • 本研究为初步经验研究,纳入10例同时性高瘤负荷转移性激素敏感性前列腺癌患者。
  • 高瘤负荷转移定义为≥4处骨转移且至少1处轴外病灶或任何内脏转移。
  • 患者需经68Ga-PSMA-11 PET/CT证实高PSMA表达,且不适合或不愿接受常规化疗联合激素治疗。
  • 177Lu-PSMA-617约5.55-7.4 GBq静脉给药,间隔8-12周,最多6个周期,所有患者同时接受雄激素剥夺治疗或睾丸切除术。

主要发现

  • 10例患者接受177Lu-PSMA-617中位累积活度32.4 GBq(范围7.4-44.4),共1-6个周期。
  • 5例(50%)在任何时间点达到血清PSA不可测(≤0.2 ng/mL),9例(90%)PSA较基线下降≥50%。
  • 9例接受影像学随访的患者中7例(77.8%)达到客观影像学缓解。
  • 中位影像学无进展生存期为24个月(95%CI 18-30),中位总生存期未达到。
  • 无患者发生任何3/4级不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 177 Lu-PSMA-617 has been shown to improve survival outcomes in patients with end-stage metastatic castration-resistant prostate cancer. However, data in earlier lines remain limited. In this study, we intended to evaluate the efficacy and safety of 177 Lu-PSMA-617 in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer (mHSPC). PATIENTS AND METHODS: Hormone-sensitive prostate cancer patients with synchronous high-volume metastases (defined as ≥4 skeletal metastases with ≥1 extra-axial site or any visceral metastasis) showing high PSMA expression on 68 Ga-PSMA-11 PET/CT and ineligible/unwilling for conventional chemohormonal treatment options were selected. Approximately, ~5.55-7.4 GBq of 177 Lu-PSMA-617 was administered intravenously at 8-12 weeks intervals, up to 6 cycles. All patients underwent concomitant androgen deprivation therapy/orchiectomy. The outcome measures included the proportion of patients achieving an undetectable serum prostate-specific antigen (PSA) (ie, ≤0.2 ng/mL) at any time point after therapy, best PSA response rate, objective radiographic response rate, radiographic progression-free survival, overall survival, and adverse events. RESULTS: Ten patients with high-volume mHSPC received a median cumulative activity of 32.4 GBq (range, 7.4-44.4) of 177 Lu-PSMA-617 over 1-6 cycles. Five patients (50%) achieved an undetectable PSA with 9 patients (90%) showing a ≥50% decline in PSA from baseline. Nine patients underwent radiological follow-up, of which 7 (77.8%) had an objective response. The median radiographic progression-free survival was 24 months (95% confidence interval, 18-30), whereas the median overall survival was not reached. None of the patients had any grade 3/4 adverse event. CONCLUSIONS: 177 Lu-PSMA-617 seems to be a promising efficacious and safe treatment option for patients with synchronous high-volume mHSPC.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Satapathy S, Yadav MP, Ballal S, et al. Promising Therapeutic Activity of 177 Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer : A Pilot Experience. Clin Nucl Med. 2023. PMID: 38049970. doi:10.1097/RLU.0000000000005000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。